Gazyva (Genentech, Inc.)
Welcome to the PulseAid listing for the Gazyva drug offered from Genentech, Inc.. This CD20-directed Antibody Interactions [MoA],CD20-directed Cytolytic Antibody [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Genentech, Inc. |
| NON-PROPRIETARY NAME: | obinutuzumab |
| SUBSTANCE NAME: | OBINUTUZUMAB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | CD20-directed Antibody Interactions [MoA],CD20-directed Cytolytic Antibody [EPC] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION, SOLUTION, CONCENTRATE |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2013-11-01 |
| END MARKETING DATE: | 0000-00-00 |
Gazyva HUMAN PRESCRIPTION DRUG Details:
| Item Description | Gazyva from Genentech, Inc. |
| LABELER NAME: | Genentech, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 1000(mg/40mL) |
| START MARKETING DATE: | 2013-11-01 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 50242-070_ea9afb84-a9dd-4d98-831e-82c822ea57b4 |
| PRODUCT NDC: | 50242-070 |
| APPLICATION NUMBER: | BLA125486 |
Other OBINUTUZUMAB Pharmaceutical Manufacturers / Labelers:
